RxDoctor Payments Data

Ronald Hsu, MD

Gastroenterology · Roseville, CANPI 1700912318

Payments from drug & device makers

$179,170in general payments, 2019–2025

Across 501 payments — averaging $357.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$117K
  • Bristol Myers Squibb$37K
  • Ferring Pharmaceuticals AS$10K
  • Ferring Pharmaceuticals Inc.$6K
  • E.r. Squibb & Sons, L.L.C.$5K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$465
  • plus $4K from 27 others

What the payments were for

  • Consulting fees$9,8587%
  • Speaking & faculty fees$93,00670%
  • Grants$3000%
  • Travel & lodging$18,29314%
  • Food & beverage$10,7988%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$179,170 in reported general payments places this provider in the 90th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$146,885
Medicare patients
486
Services billed
919

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib18$150,477
SimponiGolimumab12$81,876
ZenpepLipase/Protease/Amylase13$52,146
LinzessLinaclotide62$41,507
Mesalamine80$30,497
VemlidyTenofovir Alafenamide11$15,809
TrulancePlecanatide14$8,678
CholestyramineCholestyramine (With Sugar)24$2,464
Pantoprazole Sodium180$2,364
Omeprazole105$1,678
Famotidine55$806
Esomeprazole Magnesium28$763
Dicyclomine Hcl32$758
Budesonide EcBudesonide11$691
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Linzess$117,446$191,98480 claims
Johnson & JohnsonSimponi$384$81,87612 claims
Aimmune Therapeutics, Inc.Zenpep$127$52,14613 claims
GileadVemlidy$265$15,80911 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$465$8,67814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →